Myconostica Raised £1.7M In First Close of Series D Funding Round

Myconostica Ltd., a Manchester, UK-based medical diagnostic company developing and commercialising specific tests for life-threatening fungal infections, raised £1.7m in the first close of its Series D funding round.
The proceeds will be used to launch additional molecular diagnostic products and extend the real-time polymerase chain reaction (PCR) platforms Myconostica’s tests are able to operate on.
The company, which was founded in 2006 as a spin out from the University of Manchester, is planning to launch a test to identify Aspergillus infections, a major cause of mortality in leukaemia and transplant patients and a rapid identification system for fungi found in blood.
Myconostica also announced the appointments of Dr. Kai Deusch and John Rousseau to the Board.

Join the discussion